Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta chain and isopeptidase T in fetal Down syndrome

  • E. Engidawork
  • J.-F. Juranville
  • M. Fountoulakis
  • M. Dierssen
  • G. Lubec


The ubiquitin-proteasome proteolytic pathway is involved in an important non-lysosomal proteolytic pathway that is responsible for the highly selective turnover of cellular proteins both under basal metabolic conditions as well as stress. Protein degradation by this pathway is attributed to the 20S proteasome that forms the catalytic core of the complex. Recently there has been increasing interest in the proteasome because of its possible role in neuron degeneration and death. Fetal Down syndrome (DS) neurons were demonstrated to degenerate and undergo apoptosis in vitro. We therefore investigated the expression of different proteins involved in this degradative pathway, including subunits of the 20S proteasome, ubiquitinating and deubiquitinating enzymes, and regulatory subunits of the 26S proteasome in control and DS fetal brains by two-dimensional electrophoresis (2-DE). After 2-DE, approximately 389 protein spots were successfully identified by matrix-associated laser desorption ionization mass spectroscopy (MALDI-MS) and this was followed by quantification of twenty three proteins of the pathway. The results indicate that all but two proteins exhibited no apparent alterations in their pattern of expression. Proteasome zeta chain, an alpha subunit of the 20S proteasome (P < 0.05) and ubiquitin carboxy-terminal hydrolase T (Isopeptidase T), a deubiquitinating enzyme (P < 0.001) were significantly increased in fetal DS compared to controls. Whilst the expression of proteasome iota (n = 9, r = -0.9489, P = 0.0004) and proteasome epsilon (n = 9, r = -0.7227, P = 0.0311) chains was decreased with age in fetal DS brain, no significant correlation was obtained in the other proteins with age. The data suggest that such selective upregulation may have relevance to the developmental abnormalities that characterize this disorder.


Down Syndrome Beta Subunit Polyubiquitin Chain Ubiquitin Chain Deubiquitinating Enzyme 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahn JY, Hong SO, Kwak KB, Kang SS, Tanaka K, Ichihara A, Ha DB, Chung CH (1991) Developmental regulation of proteolytic activities and subunit pattern of 20S proteasome in chick embryo muscle. J Biol Chem 266: 15746–15749PubMedGoogle Scholar
  2. Amerik A Yu, Swaminathan S, Krantz BA, Wilkinson KD, Hochstrasser M (1997) In vivo disassembly of free polyubiquitin chains by yeast Ubp 14 modulates rates of protein degradation by the proteasome. EMBO J 16: 4826–4838PubMedCrossRefGoogle Scholar
  3. An WG, Hwang SG, Trepel JB, Blagosklonny MV (2000) Protease inhibitor induced apoptosis: accumulation of p53, p21/WAF-l/CIPl and induction of apoptosis are independent marker of proteasome inhibition. Leukemia 14: 1276–1283PubMedCrossRefGoogle Scholar
  4. Berndt P, Hobohm U, Langen H (1999) Reliable automatic protein identification from matrix-assisted laser desorption/ionization mass spectrometric peptide fingerprints. Electrophoresis 20: 3521–3526PubMedCrossRefGoogle Scholar
  5. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254PubMedCrossRefGoogle Scholar
  6. Busciglio J, Yankner BA (1995) Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro. Nature 378: 776–779PubMedCrossRefGoogle Scholar
  7. Castagne V, Gautschi M, Lefevre K, Posada A, Clarke PG (1999) Relationships between neuronal death and the cellular redox status. Focus on the developing nervous system. Prog Neurobiol 59: 397–423PubMedCrossRefGoogle Scholar
  8. Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79: 13–21PubMedCrossRefGoogle Scholar
  9. Ciechanover A, Schwartz AL (1994) The ubiquitin mediated proteolytic pathway: mechanisms of recognition of the proteolytic substrate and involvement in the degradation of native cellular proteins. FASEB J 8: 182–191PubMedGoogle Scholar
  10. Coux O, Tanaka K, Goldberg AL (1996) Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65: 801–847PubMedCrossRefGoogle Scholar
  11. DeMartino GN, Orth K, McCullough ML, Lee LW, Munn TZ, Moomaw CR, Dawson PA, Slaughter CA (1991) The primary structures of four subunits of the human high molecular weight proteinase, macropain (proteasome) are distinct but homologous. Biochim Biophys Acta 1079: 29–38PubMedCrossRefGoogle Scholar
  12. Epstein CJ (1995) Down Syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 7th edn, vol 1. McGraw Hill, New York, pp 749–794Google Scholar
  13. Fountoulakis M, Langen H (1997) Identification of proteins by matrix assisted laser desorption ionization mass spectrometry following in-gel digestion in low salt, non-volatile buffer and simplified peptide recovery. Anal Biochem 250: 153–156PubMedCrossRefGoogle Scholar
  14. Früh K, Gossen M, Wang K, Bujard H, Peterson PA, Yang Y (1994) Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex. EMBO J 13: 3236–3244PubMedGoogle Scholar
  15. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, Huber R (1997) Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 386: 463–471PubMedCrossRefGoogle Scholar
  16. Hadari T, Warms JV, Rose IA, Hershko A (1992) A ubiquitin C-terminal isopeptidase that acts on polyubiquitin chains. Role in protein degradation. J Biol Chem 267: 719–727PubMedGoogle Scholar
  17. Hilt W, Wolf DH (1996) Proteasomes: destruction as a program. Trends Biochem Sci 2: 96–102Google Scholar
  18. Hochstrasser M (1995) Ubiquitin, proteasomes and the regulation of intracellular protein degradation. Curr Opin Cell Biol 7: 215–223PubMedCrossRefGoogle Scholar
  19. Hochstrasser M (1996) Ubiquitin dependent protein degradation. Ann Rev Genet 30: 405–439PubMedCrossRefGoogle Scholar
  20. Jentsch S, Schlenker S (1995) Selective protein degradation: a journey’s end within the proteasome. Cell 82: 881–884PubMedCrossRefGoogle Scholar
  21. Keller JN, Hanni KB, Markesbery WR (2000a) Impaired proteasome function in Alzheimer’s disease. J Neurochem 75: 436–439PubMedCrossRefGoogle Scholar
  22. Keller JN, Huang FF, Markesbery WR (2000b) Decreased levels of proteasome activity and proteasome expression in aging spinal cord. Neurosci 98: 149–156CrossRefGoogle Scholar
  23. Kumatori A, Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T, Tachikawa T, Shin S, Ichihara A (1990) Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 87: 7071–7075PubMedCrossRefGoogle Scholar
  24. Langen H, Röder D, Juranville JF, Fountoulakis M (1997) Effect of the protein application mode and the acrylamide concentration on the resolution of protein spots separated by two dimensional gel electrophoresis. Electrophoresis 18: 2085–2090PubMedCrossRefGoogle Scholar
  25. Larsen CN, Krantz BA, Wilkinson KD (1998) Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37: 3358–3368PubMedCrossRefGoogle Scholar
  26. Leroy E, Boyer R, Auberger G, Leube B, Ulm G, Mezey E, et al (1998) The ubiquitin pathway in Parkinson’s disease. Nature 395: 451–452PubMedCrossRefGoogle Scholar
  27. McNaught KStP, Jenner P (2001) Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett 297: 191–194PubMedCrossRefGoogle Scholar
  28. Moazed D, Johnson AD (1996) A deubiquitinating enzyme interacts with SIR4 and regulates silencing in S. cerevisiae. Cell 86: 667–677PubMedCrossRefGoogle Scholar
  29. Murakami Y, Matsufuji S, Kameji T, Hayashi S, Igarashi K, Tamura T, Tanaka K, Ichihara A (1992) Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 360: 597–599PubMedCrossRefGoogle Scholar
  30. Naviglio S, Matteucci C, Matoskova B, Nagase T, Nomura N, Di Fiore PP, Draetta GF (1998) UBP Y: a growth regulated human ubiquitin isopeptidase. EMBO J 17: 3241–3250PubMedCrossRefGoogle Scholar
  31. Okada K, Wangpoengtrakul C, Osawa T, Toyokuni S, Tanaka K, Uchida K (1999) 4-OH-2-nonenal mediated impairment of intracellular proteolysis during oxidative stress. J Biol Chem 274: 23787–23793PubMedCrossRefGoogle Scholar
  32. Peters JM (1994) Proteasomes: protein degradation machines of the cell. Trends Biochem Sci 19: 377–382PubMedCrossRefGoogle Scholar
  33. Reinheckel T, Sitte N, Ullrich O, Kuckelkorn U, Davies KJA, Grune T (1998) Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem J 335: 637–642PubMedGoogle Scholar
  34. Reinheckel T, Ullrich O, Sitte N, Grune T (2000) Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress. Arch Biochem Biophys 377: 65–68PubMedCrossRefGoogle Scholar
  35. Rivett AJ (1998) Intracellular distribution of proteasomes. Curr Opin Immunol 10:110–114PubMedCrossRefGoogle Scholar
  36. Shapiro BL (1999) The Down syndrome critical region. J Neural Transm 57: 41–60Google Scholar
  37. Wilkinson KD, Tashayev VL, O’Connor LB, Larsen CL, Kasperek E, Pickart CM (1995) Metabolism of the polyubiquitin degradation signal: structure, mechanism, and role of isopeptidase T. Biochemistry 34: 14535–14546PubMedCrossRefGoogle Scholar
  38. Zhu Y, Carrol M, Papa FR, Hochstrasser M, D’Andrea AD (1996) DUB-1, a deubiquitinating enzyme with growth suppressing activity. Proc Natl Acad Sci USA 93: 3275–3279PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2001

Authors and Affiliations

  • E. Engidawork
    • 1
  • J.-F. Juranville
    • 2
  • M. Fountoulakis
    • 2
  • M. Dierssen
    • 3
  • G. Lubec
    • 1
  1. 1.Department of PediatricsUniversity of ViennaViennaAustria
  2. 2.F. Hoffman-La RocheBaselSwitzerland
  3. 3.Medical and Molecular Genetics CenterIRO Hospital Duran i ReynalsBarcelonaSpain

Personalised recommendations